Results 171 to 180 of about 29,210 (297)

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? [PDF]

Eur Cardiol
Esposito R, Menna P, Salvatorelli E, Camilli M, Minotti G.   +4 more
europepmc   +1 more source

CLL bei Älteren: Ibrutinib in der Erstlinie bald schon Standard? [PDF]

, 2016
Barbara Kreutzkamp
openalex   +1 more source

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

Journal of Comparative Effectiveness Research
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley   +9 more
doaj   +1 more source

Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. [PDF]

Ther Adv Hematol
Fernández de Larrea C, Loscertales J, Cabañas V, Freiria C, Blanchard MJ, Askari E, Lorenzo Pérez M, Abril L, López Pardo J, Pinzón S, Díaz Gálvez J, Amer N, Ramírez Páyer Á, García Sánchez R, Alcalá MM, Capote FJ, Moreno D, Bolumburu C, Rubio-Azpeitia E, García Sanz R.   +19 more
europepmc   +1 more source

Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma [PDF]

, 2016
Simone Critchlow, Dawn Lee, Alizée Latour, Mark Wildgust, Jeffrey L. Goldberg, Simon Rule, M Wang   +6 more
openalex   +1 more source

Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia. [PDF]

Blood Adv
Ramassone A, Pagotto S, Di Marco M, Rashid MM, Di Camillo C, Palmiero F, Innocenti I, Autore F, Tomasso A, Laurenti L, Visone R.   +10 more
europepmc   +1 more source

Ibrutinib Inhibits Platelet Integrin α _IIb β ₃ Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen

, 2015
Alexander P. Bye, Amanda J. Unsworth, Sakthivel Vaiyapuri, Alexander R. Stainer, Michael Fry, Jonathan M. Gibbins   +5 more
openalex   +1 more source

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. [PDF]

, 2017
Loretta J. Nastoupil, Matthew A. Lunning, Julie M. Vose, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Jan A. Burger, William G. Wierda, Susan O’Brien, Peter Sportelli, Hari P. Miskin, Michelle Purdom, Michael Weiss, Nathan Fowler   +14 more
openalex   +1 more source

Ibrutinib-induced pyoderma gangrenosum

Polish Archives of Internal Medicine, 2016
Andrzej Mital, Aleksandra Wilkowska, Wioletta Barańska-Rybak, Roman Nowicki, Michał Sobjanek, Martyna Sławińska   +5 more
openaire   +3 more sources

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. [PDF]

Lancet
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators.   +30 more
europepmc   +1 more source